Advertisement
Singapore markets open in 1 hour 2 minutes
  • Straits Times Index

    3,332.80
    -10.55 (-0.32%)
     
  • S&P 500

    5,460.48
    -22.39 (-0.41%)
     
  • Dow

    39,118.86
    -45.24 (-0.12%)
     
  • Nasdaq

    17,732.60
    -126.10 (-0.71%)
     
  • Bitcoin USD

    62,743.39
    +1,872.31 (+3.08%)
     
  • CMC Crypto 200

    1,301.15
    +17.32 (+1.35%)
     
  • FTSE 100

    8,164.12
    -15.56 (-0.19%)
     
  • Gold

    2,335.80
    -3.80 (-0.16%)
     
  • Crude Oil

    81.81
    +0.27 (+0.33%)
     
  • 10-Yr Bond

    4.3430
    +0.0550 (+1.28%)
     
  • Nikkei

    39,583.08
    +241.58 (+0.61%)
     
  • Hang Seng

    17,718.61
    +2.11 (+0.01%)
     
  • FTSE Bursa Malaysia

    1,590.09
    +5.15 (+0.32%)
     
  • Jakarta Composite Index

    7,063.58
    -6,967.95 (-49.66%)
     
  • PSE Index

    6,411.91
    +21.33 (+0.33%)
     

BRIEF-Wave Life Sciences Announces Positive Results From Phase 1B/2A Select-Hd Trial

June 25 (Reuters) - WAVE Life Sciences Ltd:

* WAVE LIFE SCIENCES ANNOUNCES POSITIVE RESULTS FROM PHASE 1B/2A SELECT-HD TRIAL WITH FIRST CLINICAL DEMONSTRATION OF ALLELE-SELECTIVE MUTANT HUNTINGTIN LOWERING IN HUNTINGTON’S DISEASE

* WAVE LIFE SCIENCES LTD: STATISTICALLY SIGNIFICANT INCREASES WERE OBSERVED IN WTHTT PROTEIN VERSUS PLACEBO

* WAVE LIFE SCIENCES LTD: GENERALLY SAFE AND WELL-TOLERATED PROFILE ACHIEVED IN 30 MG MULTIDOSE COHORT

* WAVE LIFE SCIENCES: SEES CURRENT CASH & CASH EQUIVALENTS SUFFICIENT TO FUND OPERATIONS INTO Q4 2025 Source text for Eikon: Further company coverage: